Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).Sumanta K. Pal, Sun Young Rha, Daniel Castellano et al.|Journal of Clinical Oncology|2021Cited by 11
A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.Hilary Glen, Sumanta K. Pal, Javier Puente et al.|Journal of Clinical Oncology|2018Cited by 4
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Carmel Pezaro, Laura Murphy et al.|The Lancet Oncology|2026Cited by 3
Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.Cristiane Decat Bergerot, Javier Puente, Sun Young Rha et al.|Journal of Clinical Oncology|2021Cited by 1